Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence (Englisch)
- Neue Suche nach: Liu, Y.
- Neue Suche nach: Hong, T.
- Neue Suche nach: Liu, Y.
- Neue Suche nach: Hong, T.
In:
Diabetes, Obesity and Metabolism
;
16
, 2
;
111-117
;
2014
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence
-
Beteiligte:
-
Erschienen in:Diabetes, Obesity and Metabolism ; 16, 2 ; 111-117
-
Verlag:
- Neue Suche nach: Blackwell Publishing Ltd
-
Erscheinungsdatum:01.02.2014
-
Format / Umfang:7 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 16, Ausgabe 2
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 97
-
Diabetes and cancer: two diseases with obesity as a common risk factorGarg, S. K. / Maurer, H. / Reed, K. / Selagamsetty, R. et al. | 2014
- 111
-
Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidenceLiu, Y. / Hong, T. et al. | 2014
- 118
-
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairmentMacha, S. / Rose, P. / Mattheus, M. / Cinca, R. / Pinnetti, S. / Broedl, U. C. / Woerle, H. J. et al. | 2014
- 124
-
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 yearsWilding, J. P. H. / Woo, V. / Rohwedder, K. / Sugg, J. / Parikh, S. / for the Dapagliflozin 006 Study Group et al. | 2014
- 137
-
Efficacy, usability and sequence of operations of a workflow‐integrated algorithm for basal–bolus insulin therapy in hospitalized type 2 diabetes patientsMader, J. K. / Neubauer, K. M. / Schaupp, L. / Augustin, T. / Beck, P. / Spat, S. / Höll, B. / Treiber, G. M. / Fruhwald, F. M. / Pieber, T. R. et al. | 2014
- 147
-
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trialKovacs, C. S. / Seshiah, V. / Swallow, R. / Jones, R. / Rattunde, H. / Woerle, H. J. / Broedl, U. C. / on behalf of the EMPA‐REG PIO™ trial investigators et al. | 2014
- 159
-
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminBolinder, J. / Ljunggren, Ö. / Johansson, L. / Wilding, J. / Langkilde, A. M. / Sjöström, C. D. / Sugg, J. / Parikh, S. et al. | 2014
- 170
-
A direct comparison of long‐ and short‐acting GLP‐1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatmentGastaldelli, A. / Balas, B. / Ratner, R. / Rosenstock, J. / Charbonnel, B. / Bolli, G. B. / Boldrin, M. / Balena, R. et al. | 2014
- 179
-
Efficacy and safety of initial combination of DPP‐IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trialsGao, W. / Dong, J. / Liu, J. / Li, Y. / Liu, F. / Yang, L. / Zhou, X. / Liao, L. et al. | 2014
- 186
-
Weight change upon once‐daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin‐naïve individuals with type 2 diabetes: results from the DIET trialNiswender, K. / Piletic, M. / Andersen, H. / Conradsen Hiort, L. / Hollander, P. et al. | 2014
- i
-
Issue Information| 2014